Correlation Between Cell Source and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both Cell Source and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cell Source and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cell Source and Novo Nordisk AS, you can compare the effects of market volatilities on Cell Source and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cell Source with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cell Source and Novo Nordisk.

Diversification Opportunities for Cell Source and Novo Nordisk

0.6

Correlation Coefficient

Cell Source  Novo Nordisk

Poor diversification

The 3 months correlation between Cell and Novo is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Cell Source and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Cell Source is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cell Source are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Cell Source i.e., Cell Source and Novo Nordisk go up and down completely randomly.

Pair Corralation between Cell Source and Novo Nordisk

Given the investment horizon of 90 days Cell Source is expected to generate 3.57 times more return on investment than Novo Nordisk. However, Cell Source is 3.57 times more volatile than Novo Nordisk AS. It trades about 0.0 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.12 per unit of risk. If you would invest  48.00  in Cell Source on December 17, 2024 and sell it today you would lose (18.00) from holding Cell Source or give up 37.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.36%
Values	Daily Returns

Cell Source  vs.  Novo Nordisk AS

Cell Source

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cell Source has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Cell Source is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Novo Nordisk AS

Risk-Adjusted Performance

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Cell Source and Novo Nordisk

The main advantage of trading using opposite Cell Source and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cell Source position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind Cell Source and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.